"SKYTyphoid Vaccine Illustration"
Drug Updates

SK bioscience Receives WHO Prequalification for Typhoid Conjugate Vaccine

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company has obtained prequalification (PQ) certification from the World Health Organization (WHO) for its typhoid conjugate vaccine (TCV), ‘SKYTyphoid®’ (project name NBP618). This the fourth WHO PQ the company has received following its […]

"PharmaTher Phase 1 Clinical Study"
Drug Updates

PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug”), has initiated its regulatory and clinical development plan to evaluate […]

"Antimicrobial Blue Light Technology"
Digital Health News

IlluminOss Subsidiary ABL Medical Developing Anti-Microbial Blue Light Fiber Technology!

ABL Medical Inc. a subsidiary of IlluminOss Medical Inc. In 2018, IlluminOss Medical began offering a system in the US that used blue light delivered via a long fiber-optic catheter to harden light-curing liquid within balloon-like orthopedic implants. Now, data from ABL Medical demonstrates that blue light with fiber-optic technology may be adapted for antimicrobial […]

Viriom AV5124 Phase I Clinical Trial Results
Drug Updates

Viriom’s Single Pill Influenza Treatment Completes Critical Phase I Clinical Trials

Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication. AV5124 is an extremely effective inhibitor of influenza virus RNA processing that is potent […]

Ixchiq: First FDA-Approved Chikungunya Vaccine
Hospital Updates

FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus

Today, the U.S. Food and Drug Administration approved Ixchiq, the first chikungunya vaccine. Ixchiq is approved for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus. The chikungunya virus is primarily transmitted to people through the bite of an infected mosquito. Chikungunya is an emerging global health threat […]

Africa CDC and SK bioscience Collaboration: Advancing Vaccine Manufacturing
Hospital Updates

Africa CDC Director General Visits SK bioscience to Discuss Vaccine Localization in Africa

SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that H.E Dr. Jean Kaseya, Director General of Africa CDC visited SK bioscience headquarters on November 3 to discuss collaboration with the Partnerships for African Vaccine Manufacturing (PAVM). Dr. Kaseya was appointed as the Director General of Africa CDC in February […]

Digital Health News

BD India Launches Rapid Molecular Technique for Detecting Multidrug-resistant Tuberculosis (MDR-TB) and other Infectious Diseases

To enable clinicians to rapidly test for TB and multidrug resistance as a first-line test, BD Diagnostics, a segment of BD Lifesciences (Becton, Dickinson, and Company), today introduced the BD MAX™ molecular diagnostic system and availability of the BD MAX™ MDR-TB panel in India.This MAX™ MDR-TB panel is included in WHO guidelines and now clinicians […]